Matt Seefeldt

Matt is an entrepreneurial scientist with extensive leadership and experience in building start-up biotechnology companies in the cell therapy and protein biologics space. With his expertise in protein chemistry and business management, Matt both developed a Phase III protein biologic (BaroFeron) and commercialized an enabling protein refolding manufacturing technology. Both these technologies were developed from research he conducted during his doctoral studies at the University of Colorado, during which he learned to bootstrap start-up biotechnology companies from the ground up. Since 2015, Matt has employed his technical expertise and start-up experience at the Gates Biomanufacturing Facility (GBF), an academic contract manufacturing organization, specializing in Cell Therapy and Protein-based Phase I biologics. As the third employee hire at the facility, Matt assisted in building out the infrastructure, installing quality systems, and managing both the Protein and Cell Therapy cGMP manufacturing groups as the GBF expanded to a 40-employee organization. Well versed in all phases of biologics manufacturing, Matt developed eight processes that have been submitted as investigation new drugs (INDs). As the Executive Director of the GBF, Matt provides operational leadership and vision to technical innovation and clinical trial support, with the ultimate goal of establishing Colorado as a leader in cell and protein manufacturing and training.